Search results
Results from the WOW.Com Content Network
Clotiazepam is metabolised to hydroxy-clotiazepam and desmethyl-clotiazepam. After oral ingestion of a single 5 mg dose of clotiazepam by three healthy volunteers the drug was rapidly absorbed. [15] The elimination half-life of the drug and its metabolites range from 6.5 hours to 18 hours. Clotiazepam is 99 percent bound to plasma protein. [15]
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...
The drug or other substance has a currently accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV. The complete list of Schedule V substances is as follows.
Noradrenergic and specific serotonergic antidepressants (NaSSAs) are a class of psychiatric drugs used primarily as antidepressants. [1] They act by antagonizing the α 2 -adrenergic receptor and certain serotonin receptors such as 5-HT 2A and 5-HT 2C , [ 1 ] but also 5-HT 3 , [ 1 ] 5-HT 6 , and/or 5-HT 7 in some cases.
Cetrelimab [5] mab: human: PD-1: cancer Cetuximab [32] Erbitux: mab: chimeric: Epidermal growth factor receptor (EGFR) Y: metastatic colorectal cancer and head and neck cancer: Cibisatamab [5] mab: humanized: CEACAM5: cancer Cilgavimab [29] mab: human: spike protein receptor binding domain (RBD) of SARS-CoV-2: US emergency use authorization ...
Cell-cycle specific chemotherapy drugs only affect cells when they are dividing, whereas cell-cycle non-specific drugs affect cells when they are at rest. [13] Lomustine is a cell cycle non-specific, highly lipophilic alkylating agent which produces chloroethyl carbenium ions and carbamylating intermediates in vivo.
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). [5] Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET A and ET B. [5]
The drug has negligible affinity for the serotonin 5-HT 2A receptor or for a variety of other targets. [ 35 ] By antagonizing the serotonin 5-HT 2C receptor, agomelatine has been found to disinhibit and increase norepinephrine and dopamine release in the frontal cortex in animals, although notably not in the striatum or nucleus accumbens .